LAKE ZURICH, Ill.--(BUSINESS WIRE)--Fenwal Inc., which was acquired by Fresenius Kabi AG last week, announced today that Dean A. Gregory has been named president, Medical Devices, for Fresenius Kabi North America. Mr. Gregory was previously senior vice president, Commercial Operations, for Fenwal.
In his new role, Mr. Gregory will continue to be responsible for North America sales and marketing for the Fenwal business, as well as the commercialization of a range of Fresenius Kabi medical devices for transfusion medicine and infusion therapy. These products are used by hospitals as well as blood and plasma collection centers.
“Dean has devoted his career to serving customers in transfusion medicine,” said John Ducker, president and CEO, Fresenius Kabi Region North America. “Fenwal has played an important role in the advancement of these therapies, and I am delighted that this long association will continue. We are pleased to have Dean join our leadership team in this new position.”
Mr. Gregory has more than 20 years of health care experience in sales, marketing, strategy and business development roles of increasing responsibility. He joined Fenwal in 2007 when the company was formed though a spin-off from Baxter International. His previous role was vice president, Business Development, Strategy and International Marketing for the Fenwal Division of Baxter International. He joined Baxter in 1991.
Mr. Gregory earned a master’s degree in business administration from DePaul University (Chicago) and a bachelor’s degree in biology from University of Illinois (Chicago). He is also a member of AABB (formerly the American Association of Blood Banks), the International Society for Blood Transfusion, and the American Marketing Association.
Fenwal, Inc., a Fresenius Kabi company, is a medical technology company focused on improving transfusion medicine through unique expertise in blood separation, collection, filtration, storage and transfusion. The company offers a broad range of products and services for the automated and manual collection of blood and blood components. Fenwal products and advanced collection and separation technologies are used worldwide. Fenwal is based in Lake Zurich, Illinois. For more information about Fenwal, please visit www.fenwalinc.com.
Fresenius Kabi (www.fresenius-kabi.com) is a leading international health care company focusing on products for the therapy and care of critically and chronically ill patients inside and outside the hospital. The company’s product portfolio comprises a comprehensive range of I.V. generic drugs, infusion therapies and clinical nutrition products as well as the medical devices for administering these products. Within transfusion technologies, Fresenius Kabi offers products for whole blood collection and processing as well as for transfusion medicine and cell therapies. Fresenius Kabi is a wholly owned subsidiary of the health care group Fresenius SE & Co. KGaA.